SARASOTA, Fla.--(BUSINESS WIRE)--RPS Diagnostics, Inc. (RPS®) today announced an updated CE mark of its FebriDx® test, clearing the way for its immediate launch in the European Union and all countries ...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured $265,000 through a share purchase plan (SPP), adding to a ...

Following its milestone CLIA waiver clearance for its FebriDx® rapid point-of-care test and the completion of a placement, Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will conduct an investor ...

In a recent JAMA Network Open study, researchers explore whether a point-of-care immunoassay called FebriDx could differentiate between bacteria- and virus-induced immune responses during acute ...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has used its March quarter update to underline a period of operational and strategic transition, as the company positions itself for expanded ...

First Australian study to use FebriDx rapid point-of-care test in a general practice primary care setting FebrixDx, which is designed to differentiate between bacterial and non-bacterial acute ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Lumos Diagnostics has initiated a ...

Lumos Diagnostics’ FebriDx to be used in Australian university study aimed at reducing unnecessary antibiotic prescribing for respiratory infections in primary care settings. FebrixDx, which is ...